Nicox, a French company headquartered in Sophia Antipolis announced that it has received Orphan Drug Designation from the FDA for naproxcinod for the treatment of Duchenne Muscular Dystrophy (DMD).  DMD is hereditary disease caused by mutations in the dystrophin gene that lead to muscle degeneration and eventual death.  It is incurable and has no effective clinical management currently. Naproxcinod is a CINOD (Cyclooxygenase-Inhibiting Nitric Oxide-Donating) anti-inflammatory medicine that showed promising preclinical results in models of muscular dystrophy.

Related Links:

http://www.nicox.com/news-media/news/nicox-receives-orphan-drug-designation-from-fda-for-naproxcinod-in-duchenne-muscular-dystrophy/